Moderna’s second quarter results were met with a negative market reaction, as investors focused on both a sharp decline in ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

The Cambridge-based vaccine maker, which became a household name during the pandemic, is cutting its global workforce to ...

Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult ...

Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, ...

Moderna is downsizing its workforce by 10% globally to bring headcount to under 5,000 in “a difficult moment for the company, ...

Moderna (MRNA) stock in focus as the company plans to cut 10% of its workforce by 2025 amid cost-saving efforts. Read more ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

Investing.com -- Moderna réduit ses effectifs mondiaux d’environ 10%, selon une lettre envoyée aux employés par le PDG ...

In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of ...